The 3rd-generation EGFR-TKI, osimertinib, has been developed to overcome EGFRT790M-mediated TKI resistance and used as a first-line therapy for EGFR-mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.